Bulletin of Pure and Applied Sciences
Zoology (Animal Science), Vol.43B, No.2s,
July-December 2024: P. 626-633

Print version ISSN 0970-0765
Online version ISSN 2320-3188

Original Research Article
Content Available online at: www.bpasjournals.com

NANOMEDICINE: REVOLUTIONIZING HEALTHCARE THROUGH INNOVATION

Parinita Tripathy[1], Suryanarayan Kumar Yadav[2], Sanyogita Shahi[3*]
[1,2,3*]Department of Science Kalinga University, Raipur Chhattisgarh, 492101 Raipur, India
Email: [3*]drsanyogitashahi@gmail.com

Abstract

Nanotechnology is therefore considered a transformative approach toward realizing innovations in medicine, drug delivery, diagnostics, imaging, and regenerative therapies. The current state-of-the-art in nanotechnology for medicine—with a focus on innovations and impacts—is presented in the following review. Nanocarriers have radically changed the field of drug delivery by increased bioavailability, targeted delivery, and controlled-release mechanisms. Such trends bring about a reduction in systemic side effects and increase the potency of the therapeutic agent. In the diagnostic field, quantum dots and iron oxide nanoparticles have greatly advanced imaging techniques, such as MRI, CT, and fluorescence imaging, which today provide superior contrast and resolution. Molecular imaging using probes based on these nanoparticles allows disease tracking at a molecular level from its early detection. Nanomaterials in regenerative medicine imitate the extracellular matrix, hence enabling tissue engineering and stem cell therapies. These materials could induce cell adhesion, proliferation, and differentiation, leading to novel tissue regeneration and rapid wound repair. Despite such a hopeful advancement, some challenges remain to be overcome besides regulatory and ethical issues. In this perspective, safety, effectiveness, and biocompatibility of the nanomaterials are really crucial points for the actual translation of the nanotherapies into clinics. Furthermore, such challenges foster interdisciplinary collaboration between basic scientists, clinicians, and industry professionals to continue the innovation of nanomedicine. This review highlights the opportunities for nanotechnology to revolutionize healthcare through the delivery of personalized, precise, and effective solutions in medicine. As research progresses, the application of nanotechnology in medical practice is expected—indeed, intended—to redefine health outcomes and eventually change the face of medicine. However, the challenges associated with it have to be harnessed if the full benefits of nanotechnology in healthcare are to be derived.

Keywords: Nanoparticles, Drug delivery, Tissue engineering, Personalized medicine, Interdisciplinary collaboration

1. Introduction

Nanotechnology has evolved to be one of the promising medical fields currently, since it involves the manipulation of matter on an atomic and molecular scale to change health care. It is a very promising area of all medical sciences, both in the fields of drug delivery and the associated diagnostic imaging, tissue engineering, and regenerative medicine aspect. Scientists have utilized nanoscale materials, and devices have achieved significant capabilities to improve the effectiveness of treatments, increase diagnostic precision, and to promote the growth of tissues. Combining nanotechnology with medicine has heralded the rise of more personalized and targeted treatments, where interventions can now be carried out with due precision at the molecular level. This combination has actually set the stage in which nanotechnology is, quite literally, going to transform health care. Highlighting important innovations through this overview, it sets out the discussion on the challenges and opportunities likely to lie ahead. As innovations and applications of the nanomedicine continue to unfold, it is then realized that interdisciplinarity and high scientific research standards are into place towards developing its full potentials for the betterment of the lot of patients and helping to define the future of medicine.

2. Literature Review

2.1. Drug Delivery Systems

Nanotechnology has revolutionized drug delivery systems by introducing advanced nanocarriers, targeted drug delivery systems, and stimuli-responsive nanoparticles.

2.1.1. Nanocarriers

Nanocarriers, basically in the form of liposomes, dendrimers, or polymeric nanoparticles, are today's mainstay in drug delivery. The nanoscale vehicles take up drugs inside them, thus protecting them from degradation and rendering controlled release profiles. Improved solubility and bioavailability of drugs—hence, it would enhance therapeutic efficacy while reducing side effects. It is in this respect that their versatility has also made it possible for many drugs to be taken and absorbed in the human body which would otherwise be poorly water-soluble compounds, hence revolutionizing the way medications are given.

2.1.2. Targeted Drug Delivery

Nanotechnology applications in targeted delivery systems involve conveyance of the therapeutic agents only to those tissues or cells affected by disease, minimizing systemic exposure and enhancing the outcome of treatment. The targeting of nanoparticles can be achieved through the functionalization of such nanoparticles with targeting moieties, including antibodies or peptides that recognize and bind to overexpressed receptors on target cells. This makes it more precise at targeting, increasing the accumulation of the drug at the site of action, therefore attaining higher therapeutic potency for the target tissue while minimizing adverse effects on healthy tissue. Such approaches to cancer treatment include targeted nanoparticles, where tumour biomarkers are used to guide the delivery of chemotherapy drugs to the malignant tumour.

2.1.3. Stimuli-Responsive Nanoparticles

Stimuli-responsive nanoparticles are designed to release drugs in response to specific environmental cues within the body, such as pH, temperature, or enzymatic activity. This responsive behavior allows for on-demand drug release at the site of disease or inflammation, optimizing therapeutic outcomes. For instance, pH-sensitive nanoparticles remain intact in the bloodstream but release their cargo in the acidic environment of tumours, maximizing drug efficacy while minimizing off-target effects. Such innovations in stimuli-responsive nanotechnology promise to revolutionize drug delivery by enhancing precision and therapeutic control in medical treatments.

2.2. Diagnostic Imaging

Nanotechnology has significantly advanced diagnostic imaging techniques through the development of nanoparticles and hybrid imaging modalities.

2.2.1. *Nanoparticles in Imaging*

They have been shown to improve the performance of conventional modalities: magnetic resonance imaging, computed tomography, and fluorescence imaging. These nanoparticles include quantum dots, gold nanoparticles, and iron oxide nanoparticles, which provide the required unique properties to enhance the contrast and resolution in the imaging process. For example, quantum dots are well known to exhibit bright fluorescence on exposure to light, which sensitively and specifically detects biomolecules in biologic samples. Iron oxide nanoparticles enhance the MRI of contrasting effects because of the magnetic property, and, at that, provide high sensitivity to detailed anatomic and functional information. The use of such nanoparticles in these imaging techniques will enhance diagnostic accuracy in a much better way in terms of sensitivity, which can help in the early detection of the disease.

2.2.2. Molecular Imaging

Molecular imaging uses nanoparticle probes to visualize some of the molecular processes taking place in living organisms. Often, these probes are conjugated with targeting molecules such as antibodies and peptides that help bind disease-specific biomarkers. Molecular imaging techniques, including positron emission tomography and single photon emission computed tomography, enable noninvasive visualization and quantification of molecular interactions, metabolic pathways, and receptor expression levels. This enables clinicians to establish very early diagnoses of diseases, follow up on their progress, and review the response to treatment with precision.

2.2.3. Hybrid Imaging Modalities

All hybrid modalities are based on at least two independent imaging techniques complementing and supplementing each other with the aid of nanoparticle-based contrast agents. For example, PET/CT and PET/MRI combine the sensitivity of a PET image with the anatomical details coming from a CT or an MRI scan. Such hybrid approaches can deliver very detailed diagnostic capabilities, thus allowing for accurate localization and characterization of diseases. Nanoparticle-enhanced hybrid imaging modalities enhance diagnosis and make formulation of personalized treatment strategies with confidence.

3. Methodology

3.1. Tissue Engineering and Regenerative Medicine

Nanotechnology has revolutionized tissue engineering and regenerative medicine by introducing novel nanomaterials, enhancing stem cell therapy, and accelerating wound healing processes.

3.1.1. Nanomaterials in Tissue Engineering

Nanomaterials, particularly nanofibers, nanostructured scaffolds, and nanocomposites, play a major role in tissue engineering. Such materials are able to replicate the structural and biochemical cues of extracellular matrixes and, therefore, give consent for cell adhesion, proliferation, and differentiation. For example, nanofibrous scaffolds exhibit large surface areas and high porosity, thus enhancing nutrient transport and waste removal while required for cell growth. At this level, nanostructured biomaterials exert exceptional tissue regeneration by guiding cellular behavior at a nanoscale level and are, therefore, very suitable for bone and cartilage repair, as well as vascular and nervous tissue regeneration.

3.1.2. Stem Cell Therapy

Nanotechnology has considerably enhanced the current prospects of stem cell therapy by providing platforms that give rise to the ability to act precisely on stem cells, behavior, and function. Nanoparticles are used for labeling stem cells for in vivo tracking and imaging, which monitors cell migration and engraftment following transplantation. Nanoparticles can deliver bioactive molecules such as growth factors and genes that regulate the differentiation of stem cells into specific lineages. It boosts the therapeutic potential of stem cells in regenerative medicine, opening up promising avenues for the treatment of degenerative diseases, reparation of damaged tissues, and organ regeneration.

3.1.3. Wound Healing

Nanotechnology-based methodologies have changed the concept of wound healing, mainly by delivering therapeutic agents into wound sites and promoting tissue regeneration. Nanoparticles carrying antimicrobial agents, growth factors, or anti-inflammatory drugs could hasten wound closure, prevent infection, and promote tissue regeneration. Nanofibrous scaffolds and hydrogels offer the required mechanical support and create a microenvironment that will perhaps foster attachment and proliferation of cells necessary to promote wound healing in both chronic and acute wounds. Such nanotechnology-enabled strategies have proved successful in the enhancement of healing outcome, reduction of scar formation, and improvement in functionality of the regenerated tissues.

4. Result and Discussion

4.1. Future Prospects and Challenges

4.1.1. Personalized Medicine

In the near future, nanotechnology holds great promise in individualized medicine, where treatments are tailored in agreement with individual genetic and molecular profiles. Personalized diagnostics and therapies have thus come of age using nanotechnology in the targeting of unique biomarkers and pathways associated with diseases. Over the next several years, nanoscale devices and nanoparticles could be tailor-made for the exact delivery of drugs or genetic material in agreement with unique physiological characteristics. The approach offers not only better treatment outcomes but also minimizes the adverse effects, hence affording the patient more personalized and effective health solutions.

4.1.2. Regulatory and Ethical Considerations

In spite of the great potential of this technology for transformation, the broad application of nanotechnology in medicine is currently suffering both from the regulatory and ethical point of view. That means ensuring the safety, efficacy, and quality of nanomaterial-based products requires robust regulatory frameworks accounting for their unique properties and potential risks. Regulatory agencies face a challenge on a global scale to define appropriate standards of safety, characterization of nanomaterials, and guidelines for establishing their use in a clinical setting. Third, by addressing ethical considerations of patient privacy, informed consent, and equal opportunities toward nanotechnology-based treatments, larger social consequences of new nanomedicine and imbalances in delivery of healthcare may be forestalled.

4.1.3. Interdisciplinary Collaboration

The next level in the application of nanotechnology in medicine will be unfolded with the concurrent cooperation of many discipline interfaces through the integration of diverse experiences in materials sciences, biology, medicine, and engineering among researchers, clinicians, engineers, and industry collaborators. The overall collaborative structure becomes a critical point in enabling the development of novel nanotechnologies from basic research through clinical translations. In turn, interdisciplinary collaboration can foster the synergy of the multiple disciplines toward new discoveries in diagnostic tools, drug delivery systems, and regenerative therapies, which will be of great use to practice healthcare and for patient treatment.

5. Conclusion

Nanotechnology has thus become a powerful factor in medicine, providing unparalleled opportunities for revolutionizing diagnostics, drug delivery, tissue engineering, and personalized medicine. Application of materials and devices at the nanoscale allowed performance of highly targeted therapies and enhancement of capabilities in imaging, while methods in regenerative medicine were improved. With nanoparticles, nanocarriers, and stimuli-responsive nanomaterials, it is expected that more effective treatments with fewer side effects will be established, considerably improving the quality of life of patients and treatment outcomes.

However, there exist considerable challenges to the full adoption of nanotechnology in medicine. In this regard, the regulatory frameworks should catch up to deal with the unique properties and potential risks of nanomaterials and ensure their safety and efficacy in clinical applications. Ethical considerations include issues of patient privacy, informed consent, and access to nanotechnology-based treatments, which need to be taken with due concern to reduce their impact on society and disparities in the delivery of health care.

6. References

1. Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), 505-515. doi:10.1021/mp800051m
2. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941-951. doi:10.1038/nbt.3330
3. Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharmaceutical Research, 33(10), 2373-2387. doi:10.1007/s11095-016-1958-5
4. Choi, H. S., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Ipe, B. I., ... & Renalda, R. (2007). Renal clearance of quantum dots. Nature Biotechnology, 25(10), 1165-1170. doi:10.1038/nbt1340
5. Dreaden, E. C., Alkilany, A. M., Huang, X., Murphy, C. J., & El-Sayed, M. A. (2012). The golden age: Gold nanoparticles for biomedicine. Chemical Society Reviews, 41(7), 2740-2779. doi:10.1039/c1cs15237h
6. Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology, and Medicine, 9(1), 1-14. doi:10.1016/j.nano.2012.05.013
7. Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer, 5(3), 161-171. doi:10.1038/nrc1566
8. Gao, J., Gu, H., & Xu, B. (2009). Multifunctional magnetic nanoparticles: Design, synthesis, and biomedical applications. Accounts of Chemical Research, 42(8), 1097-1107. doi:10.1021/ar9000026
9. Hua, S., & Wu, S. Y. (2013). The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Pharmacology, 4, Article 143. doi:10.3389/fphar.2013.00143
10. Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine, 6(4), 715-728. doi:10.2217/nnm.11.19
11. Ira Singh, Siddharth Verma, Sanyogita Shahi (2022) Biomedical Application of Carbon Nanotubes- A Review, Jundishapur Journal Of Microbiology, Vol. 15 (1), 7584-7597.
12. Jokerst, J. V., Thangaraj, M., Kempen, P. J., Sinclair, R., & Gambhir, S. S. (2012). Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods. ACS Nano, 6(7), 5920-5930. doi:10.1021/nn300705v
13. Kagan, V. E., Konduru, N. V., Feng, W., Allen, B. L., Conroy, J., Volkov, Y., ... & Star, A. (2010). Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nature Nanotechnology, 5(5), 354-359. doi:10.1038/nnano.2010.44

14. Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012). Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chemical Society Reviews, 41(7), 2971-3010. doi:10.1039/c2cs15344k
15. Kircher, M. F., de la Zerda, A., Jokerst, J. V., Zavaleta, C. L., Kempen, P. J., Mittra, E., ... & Gambhir, S. S. (2012). A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature Medicine, 18(5), 829-834. doi:10.1038/nm.2721
16. Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Molecular Pharmaceutics, 9(9), 2222-2230. doi:10.1021/mp3001325
17. Loo, C., Lowery, A., Halas, N., West, J., & Drezek, R. (2005). Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Letters, 5(4), 709-711. doi:10.1021/nl050127s
18. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991-1003. doi:10.1038/nmat3776
19. Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., ... & Thompson, M. (2009). Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials, 8(7), 543-557. doi:10.1038/nmat2442
20. Park, K. (2013). Facing the truth about nanotechnology in drug delivery. ACS Nano, 7(9), 7442-7447. doi:10.1021/nn4050109
21. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760. doi:10.1038/nnano.2007.387
22. Pragya Kadam, Sanyogita Shahi, Shirish Kumar Singh (2024), Transforming Medicine: A Comprehensive Review of Artificial Intelligence in Healthcare, Volume 6, Issue - 11 : Page: 1836-1842, doi: 10.48047/AFJBS.6.11.2024.1836-1842
23. Prow, T. W., Grice, J. E., Lin, L. L., Faye, R., Butler, M., Becker, W., ... & Roberts, M. S. (2011). Nanoparticles and microparticles for skin drug delivery. Advanced Drug Delivery Reviews, 63(6), 470-491. doi:10.1016/j.addr.2011.01.012
24. Pugazhendhi, A., Edison, T. N. J. I., Karuppusamy, I., Kathirvel, B., & Anandan, S. (2018). Influence of biogenic silver nanoparticles on lipid peroxidation, antioxidant enzyme activities, and histopathological changes in rats. Journal of Trace Elements in Medicine and Biology, 45, 76-85. doi:10.1016/j.jtemb.2017.09.010
25. Qian, X., Peng, X. H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., ... & Nie, S. (2008). In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature Biotechnology, 26(1), 83-90. doi:10.1038/nbt1377
26. Sahoo, S. K., & Labhasetwar, V. (2003). Nanotech approaches to drug delivery and imaging. Drug Discovery Today, 8(24), 1112-1120. doi:10.1016/S1359-6446(03)02978-5
27. Sapsford, K. E., Algar, W. R., Berti, L., Gemmill, K. B., Casey, B. J., Oh, E., ... & Medintz, I. L. (2013). Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology. Chemical Reviews, 113(3), 1904-2074. doi:10.1021/cr300143v
28. Sanyogita Shahi, Shirish Kumar Singh (2023), Biosynthesis Of Nanoparticles Using Milk Oligosaccharides, Journal of Advanced Zoology, Volume 44, Issue 5, Pages: 805-811, https://doi.org/10.53555/jaz.v44i5.3241
29. Sanyogita Shahi, Shirish Kumar Singh (2022), Medicinal Plants in Chhattisgarh State, Journal of Pharmaceutical Negative Reports, Vol. 13, Special Issue 5, Pages: 647-653, doi: https://doi.org/10.47750/pnr.2022.13.S05.102

30. Sanyogita Shahi, Shirish Kumar Singh, Mohammad Chand Jamali (2022),The Importance of Bioinformatics in the field of Biomedical Science, International Journal of Bioinformatics, Vol. 1, Issue 1, Pages: 1-5, https://bioinformaticsjournal.com/index.php/home
31. Sanyogita Shahi, Shirish Kumar Singh, Mohammad Chand Jamali (2022), Concepts of Nanotechnology in the examination of cells at the molecular level, International Journal of Life Sciences Biotechnology & Pharmaceutical Sciences, Vol. 1, Issue 1, Pages: 1-4, 2022, ISSN No. 2945-3143. http://ijlbps.online/index.php/home
32. Schipper, M. L., Cheng, Z., Lee, S. W., Bentolila, L. A., Iyer, G., Rao, J., ... & Wu, A. M. (2007). MicroPET-based biodistribution of quantum dots in living mice. Journal of Nuclear Medicine, 48(9), 1511-1518. doi:10.2967/jnumed.107.042614
33. Shi, J., & Votruba, A. R. (2013). Nanoscale platforms for messenger RNA delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 5(6), 530-545. doi:10.1002/wnan.1232
34. Singh, R., Lillard Jr., J. W., & Singh, S. (2009). Immunotherapy for cancer: Role of nanomaterials. Journal of Biomedical Nanotechnology, 5(1), 1-4. doi:10.1166/jbn.2009.1003
35. Sun, C., Lee, J. S., & Zhang, M. (2008). Magnetic nanoparticles in MR imaging and drug delivery. Advanced Drug Delivery Reviews, 60(11), 1252-1265. doi:10.1016/j.addr.2008.03.018
36. Torchilin, V. P. (2006). Recent advances with liposomes as pharmaceutical carriers. Nature **Reviews** Drug Discovery, 5(2), 145-160. doi:10.1038/nrd1954
37. Wagner, V., Dullaart, A., Bock, A. K., & Zweck, A. (2006). The emerging nanomedicine landscape. Nature Biotechnology, 24(10), 1211-1217. doi:10.1038/nbt1006-1211
38. Weissleder, R., & Pittet, M. J. (2008). Imaging in the era of molecular oncology. Nature, 452(7187), 580-589. doi:10.1038/nature06917
39. Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1, Article 16014. doi:10.1038/natrevmats.2016.14
40. Wu, G., Mikhailovsky, A., Khant, H. A., Fu, C., Chiu, W., Zasadzinski, J. A., & Israelachvili, J. N. (2008). Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. Journal of the American Chemical Society, 130(26), 8175-8177. doi:10.1021/ja801502g
41. Xie, J., Lee, S., Chen, X., & Nanotechnology, J. O. C. (2010). Nanoparticle-based theranostic agents. Advanced Drug Delivery Reviews, 62(11), 1064-1079. doi:10.1016/j.addr.2010.07.009